

BME - GROWTH Palacio de la Bolsa Plaza de la Lealtad, 1 28014 Madrid

Alicante, January 13th 2025

COMMUNICATION- OTHER RELEVANT INFORMATION - FACEPHI BIOMETRIA, S.A.

Dear Sirs,

Under the provisions of article 17 of the Regulation (EU) No. 596/2014 on market abuse, and article 227 of the Law 6/2023 17th March, Spanish Securities Market and Investment Services, and related provisions, as well as in the Circular 3/2020 of BME Growth, we inform you about the following information related to the company FACEPHI BIOMETRIA, S.A. (hereinafter "FacePhi" or "the Company", interchangeably).

The Company published, on May 13th, 2024, a communication of "Inside Information" regarding the agreement reached with Nice & Green for the cancellation of new convertible bond issuances (the initial investment agreement was notified to the market on May 5th, 2023, and the amendments communicated on January 19th, 2024).

On the communication from May 13th, it was also confirmed that the terms of exchange and conversion for the tranches already issued were maintained.

Consequently, Nice & Green, under the terms of the investment agreement, has notified the Company of its right to convert 60 Notes (corresponding to the 4th Tranche 2024) for a conversion amount of $\in 600,000$.

As a result of the above, the Company will grant a capital increase title deed to cover the conversion of the Notes. A total of 365,163 new shares of the Company will be issued with an issuance price of \in 1.6431 per share (\in 0.04 euros of nominal value plus issue premium \in 1.6031).

Once the capital increase title deed is granted, the share capital will be set at the sum of \in 1,031,063.36 represented by 25,776,709 shares of \in 0.04 nominal value each, numbered from 1 to 25,776,709, of the same class, equal, cumulative and indivisible.

Following the exercise of these 60 convertible bonds carried out by Nice & Green, the 4th tranche has been redeemed, and no convertible bonds remain pending conversion.

In compliance with Circular 3/2020 of the segment BME Growth of BME MTF Equity, it is expressly stated that the information hereby communicated has been produced under the sole responsibility of the company and its administrators.

We remain at your disposal for any clarification you might deem necessary. Sincerely,

Javier Mira Miró Chairman of the Board of Directors